Possible association of decreased NKG2D expression levels and suppression of the activity of natural killer cells in patients with colorectal cancer

International Journal of Oncology

Volumn 40, Issue 4, 2012, Pages 1285-1290

  Shen, Yajuan ^a   Lu, Chao ^a   Tian, Wenjun ^a   Wang, Laicheng ^a   Cui, Bin ^a   Jiao, Yulian ^a   Ma, Chunyan ^a   Ju, Ying ^a   Zhu, Ling ^a   Shao, Chunhong ^a   Liu, Xinqi ^a   Wang, Jian ^a   Zhang, Bingchang ^a   Lu, Zhiming ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Colorectal cancer; Natural killer cells; NKG2; Suppression

Indexed keywords

ANTIBODY; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MESSENGER RNA; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2D; NATURAL KILLER CELL RECEPTOR NKG2D ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL ACTIVITY; CELL LEVEL; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DEGRANULATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION;

CASE-CONTROL STUDIES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; HT29 CELLS; HUMANS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K;

EID: 84863355681     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1315     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008. (Pubitemid 351521864)
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
3. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
4. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
5. Lanier LL: NK cell receptors. Annu Rev Immunol 16: 359-393, 1998.
6. Bauer S, Groh V, Wu J, et al: Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727-729, 1999.
7. Eleme K, Taner SB, Onfelt B, et al: Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D. J Exp Med 199: 1005-1010, 2004. (Pubitemid 38481091)
8. Ota T, Takeda K, Akiba H, et al: IFN-gamma-mediated negative feedback regulation of NKT-cell function by CD94/NKG2. Blood 106: 184-192, 2005. (Pubitemid 40967191)
9. + T lymphocytes in human cervical carcinoma. Cancer Res 65: 2921-2929, 2005.
10. Lanier LL: Follow the leader: NK cell receptors for classical and nonclassical MHC class I. Cell 92: 705-707, 1998.
11. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH and Spies T: Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 96: 6879-6884, 1999. (Pubitemid 29274978)
12. Wu J, Song Y, Bakker AB, et al: An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285: 730-732, 1999.
13. Yamamoto K, Fujiyama Y, Andoh A, Bamba T and Okabe H: Oxidative stress increases MICA and MICB gene expression in the human colon carcinoma cell line (CaCo-2). Biochim Biophys Acta 1526: 10-12, 2001.
14. Gasser S, Orsulic S, Brown EJ and Raulet DH: The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436: 1186-1190, 2005. (Pubitemid 41232299)
15. Palmisano GL, Contardi E, Morabito A, Gargaglione V, Ferrara GB and Pistillo MP: HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines. Hum Immunol 66: 1-12, 2005. (Pubitemid 40037705)
16. Cao W, Xi X, Wang Z, et al: Four novel ULBP splice variants are ligands for human NKG2D. Int Immunol 20: 981-991, 2008.
17. Guerra N, Tan YX, Joncker NT, et al: NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28: 571-580, 2008.
18. Ljunggren HG: Cancer immunosurveillance: NKG2D breaks cover. Immunity 28: 492-494, 2008.
19. Melum E, Buch S, Schafmayer C, et al: Investigation of cholangio-carcinoma associated NKG2D polymorphisms in colorectal carcinoma. Int J Cancer 123: 241-242, 2008. (Pubitemid 351705216)
20. Nausch N and Cerwenka A: NKG2D ligands in tumor immunity. Oncogene 27: 5944-5958, 2008.
21. Barber A and Sentman CL: Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity. J Immunol 183: 2365-2372, 2009.
22. Berezhnoi AE, Chernisheva AD, Zakeeva IR, et al: HLA-E molecule induction on the surface of tumor cells protects them from cytotoxic lymphocytes. Vopr Onkol 55: 224-229, 2009 (In Russian).
23. Kopp R, Glas J, Lau-Werner U, Albert ED and Weiss EH: Association of MICA-TM and MICB C1-2-A microsatellite polymorphisms with tumor progression in patients with colorectal cancer. J Clin Immunol 29: 545-554, 2009.
24. Zeng XH, Sha WH, Li YY, Nie YQ, Li QN and Liang PZ: Expression of NK cells receptor NKG2D from peripheral blood in patients with primary hepatic carcinoma and its clinical significance. Zhonghua Yi Xue Za Zhi 89: 1272-1274, 2009 (In Chinese).
25. Bjorklund AT, Schaffer M, Fauriat C, et al: NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood 115: 2686-2694, 2010.
26. Kren L, Slaby O, Muckova K, et al: Expression of immune-modulatory molecules HLA-G and HLA-E by tumor cells in glioblastomas: an unexpected prognostic significance? Neuropathology 31: 129-134, 2011.
27. Zhang C, Zhang J, Sun R, Feng J, Wei H and Tian Z: Opposing effect of IFNgamma and IFNalpha on expression of NKG2 receptors: negative regulation of IFNgamma on NK cells. Int Immunopharmacol 5: 1057-1067, 2005.
28. Zhang C, Zhang J, Niu J, Zhou Z and Tian Z: Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D. Hum Immunol 69: 490-500, 2008.
29. Serrano AE, Menares-Castillo E, Garrido-Tapia M, et al: Interleukin 10 decreases MICA expression on melanoma cell surface. Immunol Cell Biol 89: 447-457, 2011.
30. Zhang J, Sun R, Wei H and Tian Z: Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy. Haematologica 89: 338-347, 2004. (Pubitemid 38788420)